Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

tremelimumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 71 Thoracic 43 Genitourinary 32 Head & Neck 22 Dermatologic 19 Other solid neoplasm 11 Breast 11 Gynecologic 10 Tumor-Agnostic 3 Sarcoma 3 Endocrine 3 Lymphoid 2 Plasma cell 1 Other neoplasm 1 Other hematologic neoplasm 1 NET 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 44 Everolimus 35 Magnetic Resonance Spectroscopy 20 Temozolomide 14 lanreotide 13 gallium Ga 68 dotatate 13 Octreotide 13 Nivolumab 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 10 pembrolizumab 9 Sunitinib 9 Specimen Handling 9 cabozantinib 8 pasireotide 7 Positron Emission Tomography Computed Tomography 7 Lutetium-177 7 3-Iodobenzylguanidine 7 Somatostatin 6 Fluorodeoxyglucose F18 6 90Y-octreotide, DOTA-Tyr(3)- 6 copper dotatate CU-64 5 amino-acid, glucose, and electrolyte solution 5 Ipilimumab 5 Injections 5 Ga(III)-DOTATOC 5 Etoposide 5 Data Collection 5 Carboplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡